This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sereno, D.
Right arrow Articles by Ouaissi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sereno, D.
Right arrow Articles by Ouaissi, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 808-812, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.808-812.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Antileishmanial Activity of Nicotinamide

D. Sereno,1* A. Monte Alegre,1 R. Silvestre,2 B. Vergnes,1 and A. Ouaissi1

U R008, Pathogénie des Trypanosomatidés, Centre IRD de Montpellier, Montpellier, France,1 Department of Biochemistry, Faculty of Pharmacy, and Institute of Cellular and Molecular Biology, University of Porto, Porto, Portugal2

Received 31 August 2004/ Returned for modification 12 October 2004/ Accepted 18 October 2004

Our study represents the first report demonstrating the antileishmanial activity of nicotinamide (NAm), a form of vitamin B3. A 5 mM concentration of NAm significantly inhibited the intracellular growth of Leishmania amastigotes and the NAD-dependent deacetylase activity carried by parasites overexpressing Leishmania major SIR2 (LmSIR2). However, the transgenic parasites were as susceptible as the wild-type parasites to NAm-induced cell growth arrest. Therefore, we conclude that NAm inhibits leishmanial growth and that overexpression of LmSIR2 does not overcome this inhibition. The mechanism of the inhibition is not defined but may include other in vivo targets. NAm may thus represent a new antileishmanial agent which could potentially be used in combination with other drugs during therapy.

* Corresponding author. Mailing address: U R008, Pathogénie des Trypanosomatidés, Centre IRD de Montpellier, Montpellier, France. Phone: 33 04 67 41 62 70. Fax: 33 04 67 41 62 20. E-mail: sereno{at}mpl.ird.fr.

Antimicrobial Agents and Chemotherapy, February 2005, p. 808-812, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.808-812.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sauve, A. A. (2008). NAD+ and Vitamin B3: From Metabolism to Therapies. J. Pharmacol. Exp. Ther. 324: 883-893 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»